Why Pharvaris (PHVS) Is Advancing Today
Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...
FDA approves first new class of painkiller in 20 years, a non-addictive opioid alternative
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
WNKY13h
Sunrise Spotlight: Hightail’n for Hadley Jo 5K
On today’s Sunrise Spotlight, News 40’s Ashlee Wilson is sitting down with Ashley Brindley. Together, they discuss the ...
JMP reiterates Kalvista stock with $19 target, sees market growth
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
KalVista initiated with an Outperform at JMP Securities
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...
Buy Rating for Astria Therapeutics: Promising Prospects in HAE and Atopic Dermatitis Markets
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...
American Association of Individual Investors2d
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
trailtimes2d
Island chiefs condemn DFO's decision to increase herring harvest
Despite a November 2024 declaration from six WSANEC chiefs calling for an immediate moratorium, Fisheries and Oceans Canada ...
'DNA doesn't lie': Study illuminates genetic diversity in North American thoroughbreds
Researchers from the University of Kentucky Martin-Gatton College of Agriculture, Food and Environment (CAFE)—in ...